DAPARIDGE M 500
TM Tablets combine Dapagliflozin, an SGLT2 inhibitor, with Metformin, a first-line antidiabetic agent, to deliver comprehensive glycemic control in patients with type 2 diabetes mellitus. This combination works through complementary mechanisms—enhancing urinary glucose excretion while improving insulin sensitivity and reducing hepatic glucose production—resulting in better overall metabolic control.
Composition
- Dapagliflozin 10 mg
- Metformin Hydrochloride 500 mg
Key Features & Benefits
- Dual Mechanism Action: Targets multiple pathways to improve glycemic control
- Enhanced Glucose Reduction: More effective than monotherapy in many patients
- Weight & Metabolic Support: Helps manage weight and improve insulin sensitivity
- Low Hypoglycemia Risk: When used appropriately under medical supervision
- Simplified Therapy: Combination reduces pill burden and improves compliance
Recommended Usage
- To be taken as directed by a healthcare professional
- Preferably taken with meals to reduce gastrointestinal side effects
- Maintain proper hydration and follow dietary guidance
Safety Information
- Not recommended in patients with severe renal impairment
- Use cautiously in patients with hepatic conditions
- Monitor for gastrointestinal side effects due to Metformin
- Regular monitoring of blood glucose and renal function is advised
Storage Instructions
- Store in a cool and dry place
- Protect from moisture and direct sunlight
- Keep out of reach of children
